© Fraunhofer ISI Seite 1 Smoke screens and sacred fires: Translational research and grand challenges in European biomedicine. Etienne Vignola-Gagné Fraunhofer.

Slides:

Advertisements

Similar presentations

Ongoing collaboration between ICT industry and the education sector needed.

Advertisements

NEWMEDS – the work leading to these results has received funding from the Innovative Medicines Initiative Joint Undertaking (IMI) NEWMEDS Novel MEthods.

1 European Clinical Research in a Global Setting FEAM Launch Event 25 January 2011 European Medical Research Councils Dr Stephane Berghmans.

Mental health strategy of the Medical Research Council (UK) Opportunities for European engagement and a role of FEAM European Parliament 22 nd March 2011.

WP8 – Innovation Support Kelly Vavasi General Secretariat for Research and Technology (GSRT) SP meeting Becici, 11 November 2010.

EU Presidency National Innovation Office Hungary Ildikó Kovács, PhD Director General International Relations Steering Platform On Research for Western.

1 FDA Industry Workshop Statistics in the FDA & Industry The Future David L DeMets, PhD Department of Biostatistics & Medical Informatics University of.

Funding system for research Research Infrastructure

Stimulating the demand for innovation – Futuris Conference April 1st 2009 Henriette van Eijl Coordinator, Lead Market Initiative EC, DG Enterprise, Innovation.

Regional and national initiatives in support of European Technology Platforms Dr. Fiona Williams Chairman, eMobility steering board

The French National Alliance for Life Sciences and Health AVIESAN Prof. André Syrota Chairman and CEO of Inserm President of Aviesan STOA, Brussels, June.

FOREST EUROPE Preparing the Sixth Ministerial Conference, including a possible legal instrument on forests EFI Annual Conference 15 September 2010, Dresden,

¨ Dr Alain Garcia General Secretary of the Rare Diseases National Plan The second National Plan for Rare Diseases in France

LIFELONG LEARNING IN THE KNOWLEDGE ECONOMY -CHALLENGES FOR TAIWAN Prof. Tsai Ching-Hwa Institute of Education, National Sun Yat-sen University Chen I-Yin.

TBD-UK: The UK response in the discovery and development of new TB drugs. Dr Geoff Coxon Deputy Leader & Director of Medicinal Chemistry, TBD-UK APPG-TB.

NMP-NCP meeting - Brussels, 27 Jan 2005 Towards FP 7: Preliminary principles and orientations… Nicholas Hartley European Commission DG Research DG Research.

Research & Innovation Evolution from IMI1 to IMI2: challenges ahead Elmar Nimmesgern, PhD DG Research & Innovation 1.

10 th October 2013 The delivery of 21 st century services – the implications for the evolution of the Healthcare Science workforce Joan Fletcher.

What Do Toxicologists Do?

National Institute on Aging Richard J. Hodes, M.D. Director,NIA/NIH/DHHS ADC Meeting – NIH Roadmap and Budget October 2003.

The National Academies’ Board on Life Sciences Dr. Frances Sharples Director National Research Council National Research Council.

1 The UK Opportunity: what is experimental medicine? UNLOCK YOUR GLOBAL BUSINESS POTENTIAL Pre- clinical development Phase I Phase II Phase III Product.

The NIH Roadmap for Medical Research

Translation of Stem Cells therapies: How to Balance Hope and Uncertainties? E. Rial-Sebbag and A. Blasimme.

The South African Malaria Initiative A Case Study E Jane Morris Bridging the Gap in Global Health Innovation - from Needs to.

TRANSLATION IN HEALTHCARE CONFERENCE EXPLORING THE IMPACT OF EMERGING TECHNOLOGIES Embedding Biobanks as Tools for Translational Research – Has the Biobank.

The New EU Framework Programme for Research and Innovation EXCELLENT SCIENCE HORIZON 2020 Peter Fisch DG RTD A.5.

The involvement of patients in Health Technology Assessment Andrzej Rys Director Health and Consumers Directorate-General Brussels 18 May 2010.

Science, research and developmentEuropean Commission Chile-EC S&T Agreement Brussels, 24 September 2002 Life Sciences, Genomics and Biotechnology for Health.

BIOPOLITICS, ETHICS AND REGENERATIVE MEDICINE João Arriscado Nunes CENTRO DE ESTUDOS SOCIAIS – LABORATÓRIO ASSOCIADO FACULDADE DE ECONOMIA DA UNIVERSIDADE.

The future prospects for clinical trials in Europe Richard Torbett Chief Economist, EFPIA.

Horizon 2020 The EU Framework Programme for Research and Innovation Health, Demographic Change and Wellbeing Lul Raka, NCP for Horizon 2020 – Health.

GOVERMENT Regulators: CQC HCPC NHS Clinical Commissioning Groups Mental Health Trusts Local Authorities Local Authority Commissioners Social Services Community.

University of Louisville Faculty Discussion on Research Ho! Ho! Ho! Happy Holidays! 1 December 10,2009.

INTRODUCTION TO RA.

PhUSE Computational Science Working Groups Solutions Through Collaboration.

A Proposal to Develop a Regulatory Science Program under Carleton University’s Regulatory Governance Initiative Presentation to the fourth Special Session.

Access to Personalised Medicine for PDAC patients STSM of the application of an EU-index for barriers Denis Horgan (EAPM) & Angela Brand (IPHG) on behalf.

ACCELERATING CLINICAL AND TRANSLATIONAL RESEARCH

1 Post-Genomics and the Future of Human Societies: a Foresight Approach Excerpts from “ DNA Analysis for Human Health in the Post- Genomic Era - An APEC-wide.

Фондация ГИС Трансфер Център г. Sofia Лектор: Kostadin Kostadiov Проект: EURESP+, ENT/CIP/10/D/

The Innovative Medicines Initiative A winning case for Joint Technology Initiative Status.

Clinical trials in Framework programme 7 (FP7) EU Judita Kinkorová 2. Národní konference o doporučených postupech, Olomouc 13. listopadu 2010.

Orphanet Europe State of the Art of Database and Services Polish activity Orphanet Europe State of the Art of Database and Services Polish.

The European agenda on improving the efficiency of employment and social policies: Bratislava, December 2011 The example of social experimentation.

Strengthening the Strategic Cooperation between the EU and Western Balkan Region in the field of ICT Research Key Barriers & Challenges in ICT Research:

Annual Meeting of the ASADI – Science Academies as Partners for Improving the Impact of Policies in Africa Session V: Partnership Themes for Development.

E u r o p e a n C o m m i s s i o nCommunity Research Global Change and Ecosystems EU environmental research : Part B Policy objectives  Lisbon strategy.

GLOBAL MARKET TRENDS The view from Pharma By Peter Knauer Executive Partner, Alliance Partnership.

EU Research and Innovation Strategies: Lessons for Thailand and Emerging Economies EU Innovation Strategy Sascha Ruhland Fraunhofer ISI, Karlsruhe.

Why Write A Grant? Elaine M. Hylek, MD, MPH Professor of Medicine Associate Director, Education and Training Division BU CTSI Section of General Internal.

Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.

1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.

NHS Confederation Annual Conference 4 June Matching Health with Growth – the UHB Story.

Research and Innovation Research and Innovation Promoting health research and innovation in Horizon 2020 Research and Innovation Research and Innovation.

Slide 1 Encouraging innovation: the regulators perspective Bringing the best to healthcare through partnership and innovation IPHA, 1 st December 2011.

Why does ERA Need to Flourish European Research Area Policy Fabienne Gautier, DG RTD, Unit ERA Policy and Reform 10 March 2016.

I farmaci innovativi in una prospettiva europea Giuseppe M.C. Rosano, MD, PhD Cardiovascular and Cell Sciences Research Institute, St George's University.

Aligning Policy Agendas The case of personalised care and cure for healthy and active ageing Setting the scene for the DG Regio and Flanders Smart Specialisation.

The opportunities and challenges of sharing genomics data with the pharmaceutical industry Shahid Hanif, Head of Health Data & Outcomes, ABPI DNA digest.

Partnerships Horizon 2020 / Eurostars expert: Dr. Radosław Piesiewicz.

From the Valley of Death to the Bridge of Life: Models for De-Risking Early Translational Projects from Around the World.

1 Dr David Coles Ethics and Science European Commission ACTIVITIES on ETHICS in The Science and Society Programme.

Moiz Bakhiet, MD, PhD, Professor and Chairman

TITIN ANDRI WIHASTUTI SCHOOL OF NURSING FACULTY OF MEDICINE

What is €5 billion worth? Magda Gunn, IMI Scientific Project Manager.

Gestora brasileiro focada exclusivamente na área da saúde.

PhUSE Computational Science

BioCapital Europe 2019, Amsterdam

Towards a Centre for New Methods

Presentation transcript:

© Fraunhofer ISI Seite 1 Smoke screens and sacred fires: Translational research and grand challenges in European biomedicine. Etienne Vignola-Gagné Fraunhofer ISI, Karlsruhe, Germany Life-Science-Governance research platform, Department of Political Science, University of Vienna, Vienna Eu-SPRI Conference 2012 “Towards Transformative Governance? Responses to mission-oriented innovation policy paradigms” 12/13 June 2012, Karlsruhe, Germany.

© Fraunhofer ISI Seite 2 What is TR? Is it a grand challenge?

© Fraunhofer ISI Seite 3 What is TR? Is it a grand challenge?

© Fraunhofer ISI Seite 4 What is TR? Is it a grand challenge? To spur biomedical innovation, the TR agenda proposes  New experimental practices: biomarkers for drug development and stratification in clinical trials, new early clinical trials models, improved animal models,...  New institutional practices: academic RTD, large public and public-private consortia, new or renewed professional roles, EMA and FDA regulations that promote innovation, …

© Fraunhofer ISI Seite 5 What is TR? Is it a grand challenge?

© Fraunhofer ISI Seite 6 What is TR? Is it a grand challenge? “The new health-related challenges that Europe and the world face today are exceptional issues that affect society at large and could be the most complex questions to be addressed in the 21st century. New paradigm shifts such as personalised medicine or innovative solutions to research issues such as the translational research gap will be needed to rapidly bring research results to patients …“ European Medical Research Councils A Stronger Biomedical Research for a Better European Future. Strasbourg: ESF.

© Fraunhofer ISI Seite 7 Arguments Focusing on argumentative practices (Fischer 2003, Gottweis 1998, Hajer 1995) in STD policy making may allow to identify a number of ‘transformative effects’; Discourse coalitions and policy narrative as privileged analytical units; Coalitional politics make certain structures and functions of innovation systems privileged targets of mobilization, and thus privileged sites of „transformative effects“;

© Fraunhofer ISI Seite 8 Following the discourses of TR in the field „Crisis in pharmaceutical R&D“ policy narrative; Discussed in journal editorials and state agencies documents; Large-scale “academic pipelines”  Sophisticated division of labor;  Large equipment traditionally found in industry;  Focuses on drug development (rather than say biologics, gene therapy, stem cell therapies, genetic diagnostic for monogenic conditions or genomic risk assessments) ;

© Fraunhofer ISI Seite 9 A case study: TRAIN

© Fraunhofer ISI Seite 10 A case study: TRAIN Through EATRIS, an ESFRI initiative – the model has an EU reach; Explicit reference to academic pipeline narrative:  „Novel translational infrastructures in academia“ (TRAIN coordinator);  „ Personalised medicine leads to smaller markets for the pharma industry“ (TRAIN researcher); Policy narrative as the main local instrument of coordination; Tensions with research teams? Puts forward different priorities than other, competing narratives.

© Fraunhofer ISI Seite 11 Further evidence

© Fraunhofer ISI Seite 12 Conclusions Argumentative policy practices - essential aspects of new models of innovation in TR? Follow the discursive practices and argumentative policy activities of specific coalitions to track the transformative effects of grand challenges on experimental and institutional practices. Grand challenges might not be only smoke screens – the sacred fire of some translational investigators, the empty rhetoric of perhaps a small group.

© Fraunhofer ISI Seite 13 Thank You! Questions? The research this presentation draws on was financed through the Translational research in genomic medicine: Institutional and social aspects “TRi-GEN” project ( as part of the ELSA-GEN initiative ( by: